Trials / Completed
CompletedNCT01261364
Pharmacogenetic-Directed Treatment for Major Depression
The Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting:A Randomized Double Blind Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Assurex Health Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Determine if antidepressant treatment guided by pharmacogenetic algorithm and interpretive report improves outcomes when compared with standard treatment without the availability of genetic information.
Detailed description
This study is designed to evaluate the clinical impact of pharmacogenetic (PGx)-directed treatment, as guided by interpretive, algorithmic report in the Pine Rest outpatient behavioral health clinics. The PGx algorithm utilized in this study is the foundation of a novel method of interpreting genetic testing results and reports them in a rapidly delivered format that provides enhanced guidance to psychiatrists in their selection of antidepressant medications
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | GeneSightRx | Multi-genetic pharmacogenomic panel |
| BEHAVIORAL | Treatment as usual | Treatment as usual |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-01-01
- Completion
- 2011-09-01
- First posted
- 2010-12-16
- Last updated
- 2015-12-03
Source: ClinicalTrials.gov record NCT01261364. Inclusion in this directory is not an endorsement.